These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24758448)

  • 1. Which oral anticoagulant to use: factor Xa inhibitor or thrombin inhibitor?
    DAS S
    Natl Med J India; 2013; 26(4):221-2. PubMed ID: 24758448
    [No Abstract]   [Full Text] [Related]  

  • 2. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Edoxaban versus warfarin for venous thromboembolism.
    Haft JI
    N Engl J Med; 2014 Jan; 370(1):80. PubMed ID: 24382070
    [No Abstract]   [Full Text] [Related]  

  • 4. Edoxaban versus warfarin for venous thromboembolism.
    Büller HR
    N Engl J Med; 2014 Jan; 370(1):80-1. PubMed ID: 24382069
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
    Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
    Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACP Journal Club. Edoxaban was noninferior to warfarin for preventing recurrent venous thromboembolism, with less bleeding.
    Thomé S
    Ann Intern Med; 2014 Jan; 160(2):JC4. PubMed ID: 24445714
    [No Abstract]   [Full Text] [Related]  

  • 7. Venous thromboembolism: Edoxaban: as effective and safer than warfarin in VTE.
    Lim GB
    Nat Rev Cardiol; 2013 Nov; 10(11):614. PubMed ID: 24042227
    [No Abstract]   [Full Text] [Related]  

  • 8. In intracranial artery stenosis, adding angioplasty and stenting to medical therapy increased stroke or death.
    Hankey GJ
    Ann Intern Med; 2014 Mar; 160(6):JC4. PubMed ID: 24638182
    [No Abstract]   [Full Text] [Related]  

  • 9. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    ; Büller HR; Décousus H; Grosso MA; Mercuri M; Middeldorp S; Prins MH; Raskob GE; Schellong SM; Schwocho L; Segers A; Shi M; Verhamme P; Wells P
    N Engl J Med; 2013 Oct; 369(15):1406-15. PubMed ID: 23991658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current status of the management of venous thromboembolism in Japan].
    Nakamura M
    Nihon Rinsho; 2014 Jul; 72(7):1298-302. PubMed ID: 25163325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral apixaban for the treatment of acute venous thromboembolism.
    Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Masiukiewicz U; Pak R; Thompson J; Raskob GE; Weitz JI;
    N Engl J Med; 2013 Aug; 369(9):799-808. PubMed ID: 23808982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial.
    Liem TK; Deloughery TG
    Semin Vasc Surg; 2011 Sep; 24(3):157-61. PubMed ID: 22153026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
    Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A
    J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
    Arepally GM; Ortel TL
    Annu Rev Med; 2015; 66():241-53. PubMed ID: 25587651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
    Marcy TR; Truong T; Rai A
    Consult Pharm; 2015 Nov; 30(11):644-56. PubMed ID: 26629800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal duration of anticoagulation after venous thromboembolism.
    Goldhaber SZ; Piazza G
    Circulation; 2011 Feb; 123(6):664-7. PubMed ID: 21321182
    [No Abstract]   [Full Text] [Related]  

  • 19. Venous Thromboembolism Prophylaxis: Safe, but Still Provocative?
    Pelargos PE; Dunn IF
    Thromb Haemost; 2019 Nov; 119(11):1716-1718. PubMed ID: 31665802
    [No Abstract]   [Full Text] [Related]  

  • 20. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
    Evans HC; Perry CM; Faulds D
    Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.